GlassScriptPhysician profile
Ashley G Shuffield
NPI 1508328253
$5,755.49
in general payments reported to CMS, 2019-2025
33 companies · $1,757 in 2025
The $1,757 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $242 · 2023: $2,047 · 2024: $1,710 · 2025: $1,757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,513.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,022.08 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $941.98 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $619.79 | 2023-2025 | |
| Lilly USA, LLC | $528.82 | 2022-2025 | Mounjaro, Zepbound, Emgality |
| Novo Nordisk INC | $494.19 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $294.27 | 2023-2025 | Otezla, Repatha, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $198.65 | 2023-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $151.63 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Ironwood Pharmaceuticals, INC | $134.00 | 2022-2024 | Linzess |
| Novartis Pharmaceuticals Corporation | $116.26 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $115.10 | 2024-2025 | Caplyta |
| Dexcom, INC. | $106.93 | 2022-2025 | Dexcom G6 Transmitter |
| Eisai INC. | $96.34 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $96.29 | 2023-2025 | Spravato |
| Exact Sciences Corporation | $93.21 | 2023-2024 | Cologuard Collection Kit |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $89.30 | 2023-2024 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $84.73 | 2022-2025 | Trintellix |
| Astellas Pharma US INC | $77.26 | 2023-2025 | Veozah |
| Antares Pharma, INC. | $71.76 | 2022-2023 | Nocdurna, Xyosted, Tlando |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.44 | 2022-2025 | Jardiance, Ofev |
| Phathom Pharmaceuticals, INC. | $69.09 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $66.18 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $60.80 | 2023-2025 | Capvaxive, Gardasil 9, Belsomra |
| Boston Scientific Corporation | $21.29 | 2025 | Watchman Flx |
| Biohaven Pharmaceutical Holding Company LTD. | $17.95 | 2022 | |
| Sumitomo Pharma America, INC. | $16.32 | 2025 | Gemtesa |
| Nevro Corp. | $16.00 | 2023 | Senza |
| Sanofi-Aventis U.S. LLC | $15.28 | 2024 | |
| Hologic Sales and Service, LLC | $14.20 | 2024 | Aptima, Thinprep 2000 Processor |
| Idorsia Pharmaceuticals US INC | $14.16 | 2024 | Quviviq |
| Currax Pharmaceuticals LLC | $13.85 | 2023 | Contrave, Onzetra Xsail |
| Xeris Pharmaceuticals, INC. | $13.44 | 2023 | Gvoke Hypopen |
| Axsome Therapeutics, INC. | $12.90 | 2025 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Shuffield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.